« Previous
Next »
Titles
- A few states fell short in timely investigation of the most serious nursing home complaints: 2011-20151
- A premium support system for Medicare: updated analysis of illustrative options1
- Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff1
- Advancement of emerging technology applications for pharmaceutical innovation and modernization1
- Affordable Care Act: IRS should mitigate limitations of data to be used for the age and gender adjustment for the tax on high-cost health plans : report to Congressional committees1
- Air ambulance: data collection and transparency needed to enhance DOT oversight : report to the Committee on Transportation and Infrastructure, House of Representatives1
- Alaska State Medicaid Fraud Control Unit: 2016 onsite review1
- An analysis of private-sector prices for hospital admissions1
- An evaluation of CBO's past outlay projections1
- Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases1
- Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters1
- Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters1
- Approaches to changing military health care1
- As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion1
- Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice1
- Biodefense: federal efforts to develop biological threat awareness : report to Congressional requesters1
- CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight1
- CMS validated hospital inpatient quality reporting program data, but should use additional tools to identify gaming1
- Calculation of potential inflation-indexed rebates for Medicare Part B drugs1
- Center for Devices and Radiological Health appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff1